Data-Driven Algorithms for Optimizing Laboratory Test Utilization for Hematologic Malignancies
This program’s overall objective is to educate hematologists, oncologists and hematopathologists about cost-effective, diagnostically efficient test ordering strategies for evaluation of erythrocytosis, myeloproliferative neoplasms, eosinophilia, mastocytosis, chronic lymphocytic leukemia, plasma cell disorders, amyloidosis and bone marrow specimens for staging of malignant lymphoma. Using test ordering algorithms based on data derived from the Mayo Clinic Hematology practice and the literature we will illustrate how costly and unnecessary biochemical, phenotypic and genetic testing can be eliminated from the participants’ practices while maintaining highest quality medical care.
PRESENTATIONS (NOW AVAILABLE)
December 5, 2014
|7-7:30 a.m.||Pre-conference Check In / Registration / Room 302, Third Level, Moscone Convention Center West|
|7:30-7:50 a.m.||Healthcare Reform and Hematology – The Value of a Laboratory and Pathology Utilization Program Slides | Video||Curtis A. Hanson, M.D.|
|7:50-8:10 a.m.||Optimal Test Utilization for Bone Marrow Staging Evaluations Slides | Video||Paul J. Kurtin, M.D.|
|8:10-8:35 a.m.||B Cell Chronic Lymphocytic Leukemia: Testing Strategies for Diagnosis, Prognosis, and Response to Therapy Slides | Video||Paul J. Kurtin, M.D.|
|8:35-8:55 a.m.||Diagnostic Algorithms for Eosinophilia and Mastocytosis Slides | Video||Curtis A. Hanson, M.D.|
|8:55-9:25 a.m.||Myeloproliferative Neoplasms in 2014: Morphology, Molecular Genetics, and Test Utilization Slides | Video||Rong He, M.D.|
|9:25-9:45 a.m.||Testing Strategies for Evaluating Patients with Hereditary Causes of Erythrocytosis Slides | Video||James D. Hoyer, M.D.|
|9:45-10:00 a.m.||Refreshment Break|
|10:00-10:30 a.m.||Plasma Cell Proliferative Disorders: A Rational Approach to the Use of the Laboratory for Diagnosis and Prognostication Slides | Video||William G. Morice, II, M.D., Ph.D.|
|10:30-11:00 a.m.||Amyloidosis, Utilization of New Diagnostic Modalities Slides | Video||Paul J. Kurtin, M.D.|
Designed for those whose practice and interests include malignant and benign hematologic disorders.
- Hospital Administration
- Laboratory Administration
- Implement new test methodologies and algorithms into practice to reduce inappropriate utilization of laboratory tests.
- Choose the optimal testing strategy for evaluation of staging bone marrow specimens for malignant lymphoma.
- Explain the intralaboratory algorithm that allows for efficient characterization of complex and rare hemoglobinopathies.
- Implement the most effective test-ordering strategy to evaluate patients with erythrocytosis.
- Select the appropriate cytogenetic and molecular genetic tests through routine laboratory tests and bone marrow biopsy findings to optimally diagnose and to predict prognosis in myeloproliferative neoplasms.
- Interpret the value of FISH testing for myelodysplasia-associated genetic abnormalities in the context of bone marrow morphology and routine cytogenetic analysis.
- Explain the efficient and effective use of hemostasis testing for the evaluation of inherited and acquired bleeding disorders.
- Describe the roles of Congo Red staining and mass spectrometry analysis for diagnosis and typing of amyloidosis.
CREDITMayo Clinic College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Mayo Clinic College of Medicine designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Curtis A. Hanson, M.D.
Paul J. Kurtin, M.D.
Rong He, M.D.
James D. Hoyer, M.D.
William G. Morice, II, M.D., Ph.D.
As a provider accredited by ACCME, Mayo Clinic College of Medicine (Mayo School of Continuous Professional Development) must ensure balance, independence, objectivity, and scientific rigor in its educational activities. Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.
National Physician Payment Transparency Program Mayo Clinic College of Medicine complies with the requirements of the National Physician Payment Transparency Program OPEN PAYMENTS (Physician Payments Sunshine Act).